Digest Network Come funziona
Network
/
Società
Io
Non verificato

Ionis Pharmaceuticals, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

66 comunicati stampa

Guarda tutti i comunicati
08/06/2026
Mercato del lavoro
Salute
Biotecnologia
Farmaceutica
Cardiologia
Ionis announces appointment of Ludwig Hantson, Ph.D. to Board of Directors
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/06/2026
Eventi
Fiere
Industria
Scienza
Cardiologia
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Ionis to present new analyses from CORE and CORE2 pivotal studies supporting olezarsen for severe hypertriglyceridemia (sHTG) at upcoming congresses
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
28/05/2026
Salute
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Industria
Ionis partner GSK announces bepirovirsen achieves unprecedented functional cure rates with potential to redefine treatment for chronic hepatitis B
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
14/05/2026
Eventi
Industria
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Ionis partner Biogen announces topline results from Phase 2 CELIA study of diranersen (BIIB080): first study to show reduction in tau pathology and cognitive benefit in patients with early Alzheimer’s disease
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
04/05/2026
Web e Social Network
Eventi
Salute
Biotecnologia
Sanità
Farmaceutica
Cardiologia
Ionis to host 2026 virtual Annual Meeting of Stockholders
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
01/05/2026
Web e Social Network
Fiere
Eventi
Salute
Biotecnologia
Farmaceutica
Cardiologia
Ionis to present at upcoming investor conferences
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
29/04/2026
Mercato azionario
Web e Social Network
Sanità
Igiene alimentare
Comunicazione
Salute
Ionis reports first quarter 2026 financial results and highlights progress on key programs
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
28/04/2026
Industria
Cardiologia
Biotecnologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Scienza
HIV, AIDS e malattie autoimmuni
Medicina - Varie
Ionis partner GSK announces bepirovirsen accepted for Priority Review and granted Breakthrough Therapy Designation by U.S. FDA as a potential first-in-class medicine for chronic hepatitis B
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
21/04/2026
Eventi
Fiere
Industria
Salute
Igiene alimentare
Sanità
Medicina - Varie
Farmaceutica
Biotecnologia
Ionis presents new data from pivotal study of zilganersen in Alexander disease (AxD) at AAN 2026 Annual Meeting
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0
15/04/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Biotecnologia
Farmaceutica
Cardiologia
Ionis to hold first quarter 2026 financial results webcast
Fonte
Ionis Pharmaceuticals, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0